Gentian Diagnostics AS (FRA:6FK) Forward Dividend Yield %: 1.60% (As of Jul. 12, 2026)


FRA:6FK Gentian Diagnostics AS FRA:6FK
73 GF Score
Price €3.47
GF Value €5.19
Valuation Significantly Undervalued
View Full Analysis

What is Gentian Diagnostics AS Forward Dividend Yield %?

Gentian Diagnostics AS FRA:6FK +3.58% 73 Forward Dividend Yield % is 1.60% as of Jul. 12, 2026. GuruFocus rates FRA:6FK with a GF Score™ of 73/100 and a GF Value™ of €5.19 (Significantly Undervalued). Among 313 Medical Devices & Instruments companies, Gentian Diagnostics AS ranks worse than 61.34% on this metric.

As of today (2026-07-12), the Forward Annual Dividend Yield of Gentian Diagnostics AS is 1.60%.

As of today (2026-07-12), the Trailing Annual Dividend Yield of Gentian Diagnostics AS is 1.60%.

FRA:6FK's Forward Dividend Yield % is ranked worse than
61.34% of 313 companies
in the Medical Devices & Instruments industry
Industry Median: 2.07 vs FRA:6FK: 1.60

Gentian Diagnostics AS's Dividends per Share for the three months ended in Jun. 2026 was €0.05.

During the past 12 months, Gentian Diagnostics AS's average Dividends Per Share Growth Rate was 50.00% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Gentian Diagnostics AS  (FRA:6FK) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Gentian Diagnostics AS Forward Dividend Yield % Related Terms


FRA:6FK vs ABT, SYK, MDT: Forward Dividend Yield % Comparison

For the Medical Devices subindustry, Gentian Diagnostics AS's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gentian Diagnostics AS Forward Dividend Yield % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Gentian Diagnostics AS's Forward Dividend Yield % falls into.


FRA:6FK
73GF Score
Gentian Diagnostics AS FRA:6FK
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gentian Diagnostics AS Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Gentian Diagnostics AS Recent Full-Year* Dividend History

Amount Ex-date Record Date Pay Date Type Frequency Forex Rate
NOK 0.6000002026-05-062026-05-072026-05-18Cash DividendannuallyNOK:EUR 0.092017

* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.

Gentian Diagnostics AS's Forward Annual Dividend Yield (%) for Today is calculated as

Forward Annual Dividend Yield=Forward Full Year Dividend/Current Share Price
=0.0552102/3.47
=1.59 %

Current Share Price is €3.47.
Gentian Diagnostics AS's Dividends per Share for the forward twelve months is calculated as €0.0552102 * 1 = €0.0552102.

Gentian Diagnostics AS's Trailing Annual Dividend Yield (%) for Today is calculated as

Trailing Annual Dividend Yield=Most Recent Full Year Dividend/Current Share Price
=0.0552102/3.47
=1.59 %

Current Share Price is €3.47.
Gentian Diagnostics AS's Dividends per Share for the trailing twelve months (TTM) ended in Today is €0.0552102.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Forward Dividend Yield % of 1.60% mean?
Gentian Diagnostics AS (FRA:6FK) has a Forward Dividend Yield % of 1.60% as of Jul. 12, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Gentian Diagnostics AS and its competitors. According to the industry distribution chart, Gentian Diagnostics AS ranks #192 out of 313 companies in the Medical Devices & Instruments industry, placing it in the top 61.3%.
Is Gentian Diagnostics AS's Forward Dividend Yield % too high?
Gentian Diagnostics AS's current Forward Dividend Yield % is 1.60%. The Medical Devices & Instruments industry median Forward Dividend Yield % is 2.07. Gentian Diagnostics AS's value of 1.60% is 22.7% below this industry median. Based on the distribution chart, Gentian Diagnostics AS ranks #192 out of 313 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Gentian Diagnostics AS has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Forward Dividend Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #192 out of 313 companies for Forward Dividend Yield %. This places Gentian Diagnostics AS in the lower half of its industry. The industry median Forward Dividend Yield % is 2.07. Gentian Diagnostics AS's value of 1.60% is 22.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Devices & Instruments company?
The median Forward Dividend Yield % among Medical Devices & Instruments companies is 2.07, based on 313 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gentian Diagnostics AS's current Forward Dividend Yield % of 1.60% is 22.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Gentian Diagnostics AS and its competitors. For the Medical Devices & Instruments industry, the median Forward Dividend Yield % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current Forward Dividend Yield % is 1.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (FRA:6FK) is currently considered Significantly Undervalued. The stock's GF Value™ is €5.19, compared to a current price of €3.47 — trading 33.1% below its estimated fair value. The current Forward Dividend Yield % is 1.60% and 22.7% below the Medical Devices & Instruments industry median of 2.07. Gentian Diagnostics AS's overall GF Score™ is 73/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Gentian Diagnostics AS (FRA:6FK), the current Forward Dividend Yield % is 1.60% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gentian Diagnostics AS (FRA:6FK) Overvalued in 2026?

Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued. The current stock price of €3.47 is trading 33.1% below its estimated GF Value™ of €5.19. GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.

Key valuation signals for FRA:6FK:

  • Forward Dividend Yield %: 1.60%
  • GF Value™: €5.19 vs. price of €3.47 (33.1% below fair value)
  • GF Score™: 73/100
  • Industry Position: 22.7% below the Medical Devices & Instruments median (#192 of 313)

No single metric tells the full story. See the FRA:6FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gentian Diagnostics AS Business Description

Other Exchanges GENTOo:SwedenGENT:Norway
Address Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
73GF Score

Get the complete analysis for FRA:6FK

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.47
Price
€5.19
GF Value